<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04049045</url>
  </required_header>
  <id_info>
    <org_study_id>ZKSJ0109</org_study_id>
    <nct_id>NCT04049045</nct_id>
  </id_info>
  <brief_title>Effects of Empagliflozin on Diuresis and Renal Function in Patients With Acute Decompensated Heart Failure</brief_title>
  <acronym>EMPAG-HF</acronym>
  <official_title>Effects of Empagliflozin on Diuresis and Renal Function in Patients With Acute Decompensated Heart Failure</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Christian Schulze</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Zentrum für Klinische Studien Jena</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Jena University Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Heart failure is the most common hospital admission diagnosis and shows increasing incidence&#xD;
      and prevalence in Germany, the United States and worldwide. Improvements in the primary&#xD;
      treatment conditions for e.g. myocardial infarction and reduced primary mortality has&#xD;
      resulted in an increasing group of patients with secondary cardiac abnormalities including&#xD;
      chronic heart failure.&#xD;
&#xD;
      Progressive cardiac dysfunction and failure are associated with exercise intolerance, volume&#xD;
      retention, nocturia, dyspnoea among others. The most severe progression of heart failure is&#xD;
      cardiac decompensation (also called: acute heart failure) and cardiogenic shock. Volume&#xD;
      retention, abnormal renal function and diuretic resistance are hallmarks of this clinical&#xD;
      phenotype. Currently, the only available treatment is diuresis through various combinations&#xD;
      of diuretics and the addition of cardiac inotropes when cardiac hypoperfusion is documented.&#xD;
      Patients with acute decompensated heart failure (ADHF) often develop a state of diuretic&#xD;
      resistance characterized by a need of rising dosages of diuretics for adequate diuresis and&#xD;
      urine production.&#xD;
&#xD;
      ADHF patients also show metabolic abnormalities including insulin resistance or type 2&#xD;
      diabetes mellitus.&#xD;
&#xD;
      Empagliflozin is a potent and selective inhibitor of the sodium glucose cotransporter 2&#xD;
      (SGLT2) used in the treatment of type 2 diabetes. By inhibiting SGLT2, empagliflozin reduces&#xD;
      renal glucose reabsorption and increases urinary glucose excretion. In addition to reducing&#xD;
      hyperglycaemia, empagliflozin is associated with osmotic diuresis, reductions in weight and&#xD;
      blood pressure without increases in heart rate, and has favourable effects on markers of&#xD;
      arterial stiffness and vascular resistance.&#xD;
&#xD;
      The investigators propose a single center exploratory study to test the hypothesis that the&#xD;
      application of empagliflozin in addition to standard diuretic regimens increases urine&#xD;
      output, decreases the need for further acceleration of diuretic regimens, and positively&#xD;
      influences renal function as well as metabolism including insulin resistance in ADHF&#xD;
      patients. Thereby, empagliflozin may be effective in the prevention of complex cardio&#xD;
      metabolic alterations involved in ADHF.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      If feasible (run-in of patients into the hospital from 08:00 a.m. to 06:00 p.m.)&#xD;
      screening/baseline, enrolment, randomization and first dose of empagliflozin should be&#xD;
      performed on the same day. In general, but especially in case of other run-in times (e.g.&#xD;
      late evening, night and early morning hours) screening/baseline time period should not exceed&#xD;
      12 hours. In case a patient has to spend the night in hospital before randomization can be&#xD;
      executed, a time period of up to 16 hours will not be counted as protocol deviation.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 29, 2019</start_date>
  <completion_date type="Actual">June 29, 2021</completion_date>
  <primary_completion_date type="Actual">May 30, 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Single-center, prospective, double-blind, placebo-controlled, randomized and interventional exploratory study</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
    <masking_description>There will be two trial medications, the licensed medicinal product empagliflozin, trade name Jardiance®, 25 mg and matching placebo tablets. The placebo tablets will be indistinguishable by appearance, taste, smell, weight from the investigational product. Both will be stored in plastic containers containing 30 tablets each.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Total urinary output (UOP) as measured by daily volume summed up over 5 days</measure>
    <time_frame>5 days</time_frame>
    <description>Total UOP as summed over 5 days</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Renal function under treatment</measure>
    <time_frame>5 days</time_frame>
    <description>Change of creatinine values: increase in creatinine of &gt; 0.3 mg/dl, doubling of serum creatinine, need for renal replacement therapy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Net fluid output</measure>
    <time_frame>5 days</time_frame>
    <description>UOP - fluid intake</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Worsening or persistent heart failure</measure>
    <time_frame>30 days</time_frame>
    <description>NYHA class (New York Heart Association functional heart failure classification)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Intermediate Care (IMC) / Intensive Care Unit (ICU) and hospital length of stay</measure>
    <time_frame>30 days</time_frame>
    <description>Duration in days</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Liver function</measure>
    <time_frame>30 days</time_frame>
    <description>bilirubin, serum aminotransferases, relevant change in coagulation status</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pulmonary function</measure>
    <time_frame>30 days</time_frame>
    <description>oxygen saturation without oxygen therapy/ need for oxygen in l/min, presence of rales, changes in chest x-ray (worsening/ improvement/ new infiltration)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients alive and out of hospital -after 30 days</measure>
    <time_frame>30 days</time_frame>
    <description>number of patients</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Safety Outcome: Number of Adverse Events and Serious Adverse Events including MedDRA-SAE Preferred Terms and SOCs in both groups</measure>
    <time_frame>30 days</time_frame>
    <description>Listing of all adverse events and serious adverse events, laboratory parameters as far as not efficacy parameters</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">60</enrollment>
  <condition>Acute Decompensated Heart Failure</condition>
  <arm_group>
    <arm_group_label>Verum arm</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>25 mg tablet of empagliflozin once daily for five days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo arm</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>one tablet of the matching Placebo once daily for five days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Empagliflozin 25 mg</intervention_name>
    <description>Empagliflozin 25 mg film-coated tablets, for oral use administered once daily for 5 days in addition to routinely administered (weight adjusted) intravenous furosemide</description>
    <arm_group_label>Verum arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>matching Placebo, film-coated tablets, for oral use, matching to investigational product Jardiance® administered once daily for 5 days in addition to routinely administered (weight adjusted) intravenous furosemide</description>
    <arm_group_label>Placebo arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients (age between 18-85 years) with acute decompensated heart failure (HF).&#xD;
&#xD;
          -  Brain Natriuretic Peptide (BNP) &gt;100 pg/ml, or N-terminal pro-BNP (NT-proBNP)&gt;300&#xD;
             pg/ml as defined by current clinical guidelines for the diagnosis of acute&#xD;
             decompensated HF (European Society of Cardiology 2016 HF guideline)&#xD;
&#xD;
          -  Patients with diabetes mellitus type 2 or impaired glucose tolerance as defined by&#xD;
             current clinical guidelines (German and International Diabetes Society 2016: HbA1c&gt;6.5&#xD;
             % (upper limit for this clinical trial 12 %) or fasting glucose &gt;7.0 mmol/l or any&#xD;
             incidental glucose level &gt;11.1 mmol/l or abnormal oral glucose tolerance test with 2h&#xD;
             plasma glucose &gt;7.8 mmol/l) or on antidiabetic medication or antidiabetic diet or&#xD;
             patients with normal Glucose tolerance&#xD;
&#xD;
          -  Patients without cognitive impairment, i.e. they must be capable of understanding the&#xD;
             nature, significance and implications of the clinical trial and to form a rational&#xD;
             intention in the light of the facts&#xD;
&#xD;
          -  Written informed consent obtained&#xD;
&#xD;
          -  For women with childbearing potential (until 2 years after menopause):&#xD;
&#xD;
               -  Negative pregnancy test&#xD;
&#xD;
               -  regular and correct use of a highly effective contraceptive method with an error&#xD;
                  rate of &lt;1% per year (e.g. combined (estrogen and progesteron) hormonal&#xD;
                  contraception (oral, intravaginal, transdermal), progesteron-only hormonal&#xD;
                  contraception (oral, injectable, implantable), intrauterine device (IUD),&#xD;
                  intrauterine hormone-releasing system (IUS) tubal ligation (female&#xD;
                  sterilization), hormon donating intrauterine device (&quot;hormonal spiral&quot;), double&#xD;
                  barrier methods, sexual abstinence, vasectomy of the partner)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Type 1 diabetes mellitus&#xD;
&#xD;
          -  Chronic Kidney Disease (CKD) with eGFR&lt; 30 ml/min, or end-stage renal failure with the&#xD;
             need for chronic dialysis treatment&#xD;
&#xD;
          -  Acute kidney injury (AKI) ≥ Acute Kidney Injury Network (AKIN) stage 2 or requiring&#xD;
             dialysis treatment&#xD;
&#xD;
          -  Current medication with SGLT-2 inhibitors&#xD;
&#xD;
          -  Known intolerance or hypersensitivity to the active substance empagliflozin, lactose&#xD;
             or any other of the excipients listed in section 6.1. of the summary of product&#xD;
             characteristics (SmPC). A contraindication or intolerance to furosemide&#xD;
&#xD;
          -  Acute heart failure without signs of congestion (&quot;dry&quot; patient)&#xD;
&#xD;
          -  Indication for urgent coronary angiography or any planned administration of a iodine&#xD;
             based contrast agent within the next 6 days&#xD;
&#xD;
          -  Need for hemofiltration or any other form of extracorporeal therapy&#xD;
&#xD;
          -  Planned surgery&#xD;
&#xD;
          -  Previous participation in this trial or recent participation in another clinical trial&#xD;
             (within the last 3 months before inclusion, so that medical product/s from previous&#xD;
             trial participation/s have been fully washed out )Identification of any causes of&#xD;
             heart failure leading to decompensation that needs urgent management (like acute&#xD;
             coronary syndrome, severe unstable arrhythmias, mechanical causes, acute pulmonary&#xD;
             embolism)&#xD;
&#xD;
          -  Incapacity to understand and / or to provide written informed consent&#xD;
&#xD;
          -  Ongoing reported alcohol abuse (daily alcohol intake of more than 2 drinks (liquor,&#xD;
             beer or wine) in men and 1 drink in women, corresponding to 12/24 g of pure alcohol&#xD;
             per day women / men and/ or obvious alcoholisation of the patient during screening )&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Christian Schulze, Prof. Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Internal Medicine I, Jena University Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Department of Internal Medicine I, Jena University Hospital</name>
      <address>
        <city>Jena</city>
        <zip>07747</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>July 10, 2019</study_first_submitted>
  <study_first_submitted_qc>August 6, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">August 7, 2019</study_first_posted>
  <last_update_submitted>July 27, 2021</last_update_submitted>
  <last_update_submitted_qc>July 27, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 3, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Jena University Hospital</investigator_affiliation>
    <investigator_full_name>Christian Schulze</investigator_full_name>
    <investigator_title>Prof. Dr. med. P. Christian Schulze</investigator_title>
  </responsible_party>
  <keyword>acute decompensated heart failure</keyword>
  <keyword>empagliflozin</keyword>
  <keyword>diuresis</keyword>
  <keyword>renal function</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Empagliflozin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

